Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645497 | 0.86 | ROCK2 (0.58) | LMNAMAPK1NLRP1ROCK2ROCK1 | |
| SCHEMBL5643117 | 0.86 | LMNA (0.71) | LMNAMAPK1NLRP1ROCK2ROCK1 | |
| SCHEMBL5643080 | 0.86 | SMN1; SMN2 (0.57) | LMNAMAPK1NLRP1ROCK2ROCK1 | |
| SCHEMBL5643140 | 0.86 | EPHX2 (0.54) | EPHX2NR1H4 | |
| SCHEMBL23021932 | 0.77 | ROCK2 (0.70) | ROCK2ROCK1EPHX2P2RX7 | |
| SCHEMBL21724695 | 0.77 | HSD11B1 (0.58) | LMNAP2RX7HSD11B1 | |
| SCHEMBL2831744 | 0.76 | P2RX7 (0.56) | LMNAP2RX7HSD11B1 | |
| SCHEMBL6357659 | 0.76 | TP53 (0.56) | ROCK2ROCK1P2RX7 | |
| SCHEMBL6357645 | 0.75 | ALDH1A1 (0.53) | LMNAMAPK1NLRP1ROCK2ROCK1 | |
| SCHEMBL3727336 | 0.75 | HSD11B1 (0.55) | LMNAP2RX7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| CN-1768050-A | Benzopyran compounds for the treatment of inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | LMNA 3346/4885MAPK1 2487/4885NLRP1 279/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | LMNA 2102/4885MAPK1 2323/4885NLRP1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.